申请人:MOCHIDA PHARMACEUTICAL CO., LTD.
公开号:EP1048640A1
公开(公告)日:2000-11-02
Apoptosis inhibitors containing as the active ingredient compounds represented by general formula (I) or salts thereof, wherein W1 represents -O-, -CH2-, etc.; W2 represents -CH2-, etc.; W3 represents -O-, -CH2-, etc.; X represent CH, C-, etc.; and A represents formula (α) wherein W4 represents -O-, -CH2-, etc.; W5 represents -CH2 -, etc.; and W6 represents -O-, CH2 -, etc. These apoptosis inhibitors inhibit apoptosis of WC8 cells induced by Fas ligand. In animal models, they potently inhibit the progress of fulminant hepatitis and relieve alopecia caused by anticancer agents. Because of being highly safe, these apoptosis inhibitors are usable as beneficial drugs.
含有一般式(I)或其盐所代表的化合物作为活性成分的凋亡抑制剂,其中,W1代表-O-,-CH2-等;W2代表-CH2-等;W3代表-O-,-CH2-等;X代表CH,C-等;A代表公式(α),其中W4代表-O-,-CH2-等;W5代表-CH2-,等;W6代表-O-,CH2-等。这些凋亡抑制剂能够抑制Fas配体诱导的WC8细胞的凋亡。在动物模型中,它们能够强烈抑制暴发性肝炎的进展并缓解由抗癌药物引起的脱发。由于具有高度的安全性,这些凋亡抑制剂可用作有益的药物。